Blood pressure first-line just changed: PBS now covers dual therapy from day one

One in three Australian adults has high blood pressure. Of those, roughly one in three has it controlled to target.

That is not a knowledge failure. Most people with hypertension have been told they have it. Most have been prescribed something. The gap between diagnosis and controlled blood pressure is a different kind of problem — part clinical inertia, part prescribing habit, part a PBS structure that previously made it harder to start where the evidence points: with two drugs from the beginning.

That structure just changed.

From 1 April 2026, the PBS no longer requires a monotherapy trial before accessing fixed-dose combination (FDC) antihypertensives. Dual therapy single-pill combinations are now listed as Unrestricted Benefit for standard 30-day prescriptions, and as Restricted Benefit for 60-day scripts in stable patients. A patient whose blood pressure is above 140/90 mmHg can now start on a two-drug combination from day one, at PBS prices.

This is the recommendation that the National Hypertension Taskforce of Australia has been calling for since 2024, and it brings Australia into alignment with every major international hypertension guideline.

---

The both-and

The clinical case for combination therapy as first-line is not new — and the delay in acting on it has been expensive. Hold both.

The evidence side. Every major international hypertension guideline — ESC, AHA, NICE — has recommended starting most patients with stage 2 hypertension (above 140/90 mmHg) on a two-drug combination rather than monotherapy. The reason is mechanistic: two agents at half dose produce more blood pressure reduction than one agent at full dose, with fewer side effects. Compliance is also higher with a single pill than with two separate tablets. A 2026 Australian Prescriber analysis notes that starting with dual therapy is more effective than monotherapy for most individuals with blood pressure above 140/90 mmHg, and will likely be strongly recommended for those above 160/95 mmHg in the forthcoming 2026 Australian guideline.

The PBS-listed combinations include perindopril + amlodipine, telmisartan + amlodipine, and irbesartan + hydrochlorothiazide. These are well-established drug pairings — ACE inhibitor or ARB combined with a calcium channel blocker — that address blood pressure through complementary mechanisms. The PBS change does not introduce new drugs. It removes a structural obstacle to using established drugs the way the evidence supports.

The inertia side. The PBS change removes the prescribing barrier. It doesn’t automatically resolve the clinical conversations that haven’t happened yet. Many Australian women in the perimenopause transition see their blood pressure rise without understanding why — oestrogen has vasodilatory effects, and its decline contributes to increased peripheral resistance. Blood pressure that was 115/75 at 40 can shift meaningfully by 50 without any other lifestyle change. That shift rarely gets named in the consultation, because the consultation is already busy.

Similarly, the cardiovascular risk framing that guides treatment decisions — whether to target 130 mmHg systolic for a high-risk patient versus 140 mmHg for a lower-risk one — requires individual risk assessment that takes time. The forthcoming 2026 Australian hypertension guideline is expected to formalise lower treatment targets, better measurement standards (particularly around out-of-office readings), and greater uptake of combination therapy. That guideline will provide clearer structure for those decisions. Until then, the PBS change is the practical signal.

---

2 cents

If you have been on a single antihypertensive medication for years and your blood pressure has not reached target — a conversation about adding a second agent (or switching to a fixed-dose combination) is worth having now. The PBS no longer requires you to have failed monotherapy first. That is a change your GP may not yet have acted on, because the change is recent and consulting rooms are busy.

The specific choice of which combination depends on your clinical picture: kidney function, diabetes status, whether you have coronary disease, how your current drug is sitting. That is the individual conversation. But the PBS barrier that previously stood in the way of that conversation — gone.

This is general information. Blood pressure targets and medication choices are individual — what applies here may not apply to your specific history, risk profile, or current medications. The specific version of this is the consulting-room conversation.

---

Verdict

Verdict: yes — worth knowing about.

The PBS change to first-line dual antihypertensive therapy is real, it is live, and it removes a structural obstacle that has contributed to Australia’s blood pressure control gap for years. One in three adults with hypertension, one in three of those controlled — that arithmetic has been resistant to change. The evidence for combination therapy has been available for years. The prescribing pathway now reflects it. For anyone on a single antihypertensive that isn’t reaching target, the prompt is in: revisit the conversation.

---

Sources cited

1. Hypertension — a major modifiable and undertreated risk factor — Australian Prescriber
2. PBS restriction changes for antihypertensive dual therapy fixed dose combinations
3. Simpler treatment, better outcomes — PBS reforms improve blood pressure control — Medianet
4. National Hypertension Taskforce of Australia: roadmap to 70% control by 2030 — MJA
5. Blood pressure single pills added to PBS — Heart Foundation